Form 4: Alignment Healthcare CEO John Kao Sells 298,000 Shares

CEO John Kao executed a planned sale of 298,000 shares of Alignment Healthcare common stock under a Rule 10b5-1 trading plan.

Summary

• CEO John Kao sold a total of 298,000 shares of Alignment Healthcare (ALHC) common stock on June 10, 2026.
• The sales were executed in two tranches: 74,936 shares at a weighted average price of $19.6481 and 223,064 shares at a weighted average price of $20.5962.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 21, 2025.
• Following the transactions, the reporting person retains beneficial ownership of 1,386,766 shares held via the JEK Trust and 1,608,743 shares held directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be optically negative, the use of a pre-planned 10b5-1 arrangement suggests routine financial management rather than a reaction to negative internal developments.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell stock without triggering insider trading concerns.

Negatives

• Significant divestment of equity by the Chief Executive Officer may be perceived by some market participants as a lack of long-term confidence or a signal that the stock is fully valued.

Risks

• Market volatility associated with executive selling activity.
• Potential negative sentiment from retail investors regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that executive selling via 10b5-1 plans is a common practice in the healthcare technology and managed care sectors, often used for personal financial planning rather than reflecting fundamental changes in company outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at companies like UnitedHealth Group or Humana to manage equity holdings while maintaining regulatory compliance.

Related Party Transactions

• Transfer of 176,125 shares from direct ownership to the JEK Trust, of which the CEO is the trustee.

Stakeholder Impact

• Shareholders may experience minor price volatility following the disclosure of significant insider selling.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Alignment Healthcare, ALHC, Insider Trading, Form 4, John Kao, Stock Sale